Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REVIVA PHARMACEUTICALS HOLDINGS, INC.RVPH · Entity 8147 | Chief Financial Officer | March 18, 2026 | March 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REVIVA PHARMACEUTICALS HOLDINGS, INC.
Report date March 18, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.87 · Expires 2036-03-17 | Direct | 40,925 |
Reported balance
After 2026-03-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-18 · Grant · Acquired 40,925 · Balance 40,925 F1: This option award was made on March 18, 2026 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option provides for vesting as follows: (i) 12,789 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 28,136 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: This option award was made on March 18, 2026 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option provides for vesting as follows: (i) 12,789 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 28,136 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 18, 2026 Filed Mar 20, 2026 21:00 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | GrantStock Option (right to buy) · Derivative | 40,925 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001437749-26-009260 · rdgdoc.xml · derivative · entry 1 Prabhu Narayan · CIK 0001829831 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,925 Underlying: Common Stock, par value $0.0001 per share · 40,925 shares Expires 2036-03-17 F1 · derivative.exercise_date: This option award was made on March 18, 2026 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option provides for vesting as follows: (i) 12,789 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 28,136 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | GrantStock Option (right to buy) · Derivative | 194,250 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001437749-25-004221 · rdgdoc.xml · derivative · entry 1 Narayan Prabhu · CIK 0001829831 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,250 Underlying: Common Stock, par value $0.0001 per share · 194,250 shares Expires 2035-02-12 F1 · derivative.exercise_date: The option award was made on February 13, 2025 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option provides for vesting as follows: (i) 80,938 of the shares subject to the option are immediately vested on the Grant Date, (ii) 89,043 shares subject to the option will vest in equal installments on the last day of each month from March 2025 to December 2026, and (iii) 24,269 shares subject to the option will vest in equal installments on the last day of each month from January 2027 to December 2027. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan. Read SEC document |
| September 15, 2024 Filed Sep 17, 2024 21:01 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | GrantStock Option (right to buy) · Derivative | 96,519 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001437749-24-029387 · rdgdoc.xml · derivative · entry 1 Narayan Prabhu · CIK 0001829831 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,519 Underlying: Common Stock, par value $0.0001 per shae · 96,519 shares Expires 2034-09-14 F1 · kind: Represents an option award (the "Option") granted to Mr. Narayan Prabhu, the Issuer's Chief Financial Officer (the "Reporting Person"), by the Issuer's compensation committee (the "Compensation Committee") on September 15, 2024 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). On the Grant Date, the Compensation Committee determined the amount of incentive bonus earned by Mr. Prabhu for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment. The Option, which is fully vested on the Grant Date, represents payment of Mr. Prabhu's incentive bonus earned for 2023. The exercise price of the Option is based on the closing price of the Issuer's common stock on September 13, 2024, in accordance with the terms of the 2020 Plan. F1 · derivative.exercise_date: Represents an option award (the "Option") granted to Mr. Narayan Prabhu, the Issuer's Chief Financial Officer (the "Reporting Person"), by the Issuer's compensation committee (the "Compensation Committee") on September 15, 2024 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). On the Grant Date, the Compensation Committee determined the amount of incentive bonus earned by Mr. Prabhu for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment. The Option, which is fully vested on the Grant Date, represents payment of Mr. Prabhu's incentive bonus earned for 2023. The exercise price of the Option is based on the closing price of the Issuer's common stock on September 13, 2024, in accordance with the terms of the 2020 Plan. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 20:30 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | GrantStock Option (right to buy) · Derivative | 170,000 | $0.00 Strike: $6.74 | $0.00 |
DisclosureSEC source: 0001437749-23-011378 · rdgdoc.xml · derivative · entry 1 Narayan Prabhu · CIK 0001829831 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock, par value $0.0001 per share · 170,000 shares Expires 2033-04-24 F1 · derivative.exercise_date: Represents an option award granted to Mr. Narayan Prabhu, the Issuer's Chief Financial Officer (the "Reporting Person"), by the Issuer's compensation committee on April 25, 2023 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option vested as to fifty percent (50%) of the shares subject thereto on the Grant Date, and will vest as to an additional 1.389% of the shares subject thereto on the last day of each month thereafter. The exercise price is based on the closing price of the Issuer's common stock on the Grant Date in accordance with the terms of the 2020 Plan. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 21:01 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | PurchaseCommon Stock, par value $0.0001 per share | 50,000 | $1.66 | $83,000.00 |
DisclosureSEC source: 0001437749-22-023485 · rdgdoc.xml · nonDerivative · entry 1 Narayan Prabhu · CIK 0001829831 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Read SEC document |
| June 30, 2022 Filed Jun 30, 2022 21:52 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | PurchaseCommon Stock, par value $0.0001 per share | 50,000 | $1.21 | $60,670.00 |
DisclosureSEC source: 0001437749-22-016306 · rdgdoc.xml · nonDerivative · entry 1 Narayan Prabhu · CIK 0001829831 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.08 to $1.37 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 21:09 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001437749-21-009050 · rdgdoc.xml · derivative · entry 1 Narayan Prabhu · CIK 0001829831 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock, par value $0.0001 per share · 50,000 shares Expires 2031-04-13 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The Option will vest at the rate of twenty-five percent (25%) of the shares subject thereto upon the one year anniversary of Mr. Prabhu's employment with the Company, and as to an additional 2.0833% of the shares on the last day of each month thereafter. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.